Literature DB >> 15521192

Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment.

Jirí Bajgar1.   

Abstract

OP/nerve agents are still considered as important chemicals acting on living organisms and are widely used. They are characterized according to their action as compounds influencing cholinergic nerve transmission via inhibition of AChE. Modeling of this action and extrapolation of experimental data from animals to humans is more possible for highly toxic agents than for the OP. The symptoms of intoxication comprise nicotinic, muscarinic, and central symptoms; for some OP/nerve agents, a delayed neurotoxicity is observed. Cholinesterases (AChE and BuChE) are characterized as the main enzymes involved in the toxic effect of these compounds, including molecular forms. The activity of both enzymes (and molecular forms) is influenced by inhibitors (reversible, irreversible, and allosteric) and other factors, such as pathological states. There are different methods for cholinesterase determination; however, the most frequent is the method based on the hydrolysis of thiocholine esters and subsequent detection of free SH-group of the released thiocholine. The diagnosis of OP/nerve agent poisoning is based on anamnesis, the clinical status of the intoxicated organism, and on cholinesterase determination in the blood. For nerve agent intoxication, AChE in the red blood cell is more diagnostically important than BuChE activity in the plasma. This enzyme is a good diagnostic marker for intoxication with OP pesticides. Some other biochemical examinations are recommended, especially arterial blood gas, blood pH, minerals, and some other specialized parameters usually not available in all clinical laboratories. These special examinations are important for prognosis of the intoxication, for effective treatment, and for retrospective analysis of the agent used for exposure. Some principles of prophylaxis against OP/nerve agent poisoning comprising the administration of reversible cholinesterase inhibitors such as pyridostigmine (alone or in combination with other drugs), scavengers such as preparations of cholinesterases, some therapeutic drugs, and possible combinations are given. Basic principles of the treatment of nerve agent OP poisoning are described. They are based on the administration of anticholinergics (mostly atropine but some other anticholinergics can be recommended) as a symptomatic treatment, cholinesterase reactivators as a causal treatment (different types but without a universal reactivator against all OP/nerve agents) as the first aid and medical treatment, and anticonvulsants, preferably diazepam though some other effective benzodiazepines are available. New drugs for the treatment are under experimental study based on new approaches to the mechanism of action. Future trends in the complex research of these compounds, which is important not only for the treatment of intoxication but also for the quantitative and qualitative increase of our knowledge of toxicology, neurochemistry, neuropharmacology, clinical biochemistry, and analytical chemistry in general, are characterized.

Entities:  

Mesh:

Year:  2004        PMID: 15521192     DOI: 10.1016/s0065-2423(04)38006-6

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  104 in total

1.  Two step synthesis of a non-symmetric acetylcholinesterase reactivator.

Authors:  Kamil Musilek; Kamil Kuca; Vlastimil Dohnal; Daniel Jun; Jan Marek; Vit Koleckar
Journal:  Molecules       Date:  2007-08-07       Impact factor: 4.411

2.  Antimicrobial, antimalarial, and antileishmanial activities of mono- and bis-quaternary pyridinium compounds.

Authors:  Sandip B Bharate; Charles M Thompson
Journal:  Chem Biol Drug Des       Date:  2010-10-11       Impact factor: 2.817

3.  Methylacridinium and its cholinergic properties.

Authors:  Ondrej Soukup; Jan Proska; Jiri Binder; Jana Zdarova Karasova; Gunnar Tobin; Daniel Jun; Jan Marek; Kamil Musílek; Josef Fusek; Kamil Kuca
Journal:  Neurotox Res       Date:  2009-06-30       Impact factor: 3.911

4.  Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman.

Authors:  Trond Myhrer; Siri Enger; Pål Aas
Journal:  Neurochem Res       Date:  2007-08-21       Impact factor: 3.996

5.  Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.

Authors:  Sandip B Bharate; Lilu Guo; Tony E Reeves; Douglas M Cerasoli; Charles M Thompson
Journal:  Bioorg Med Chem       Date:  2009-11-27       Impact factor: 3.641

6.  Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates.

Authors:  S Kaleem Ahmed; Yamina Belabassi; Lakshmi Sankaranarayanan; Chih-Kai Chao; John M Gerdes; Charles M Thompson
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

7.  Acute toxicity of organophosphorus compounds in guinea pigs is sex- and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition.

Authors:  William P Fawcett; Yasco Aracava; Michael Adler; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

8.  Biomonitoring of organophosphorus agent exposure by reactivation of cholinesterase enzyme based on carbon nanotube-enhanced flow-injection amperometric detection.

Authors:  Dan Du; Jun Wang; Jordan N Smith; Charles Timchalk; Yuehe Lin
Journal:  Anal Chem       Date:  2009-11-15       Impact factor: 6.986

9.  Metoclopramide protection of diazinon-induced toxicosis in chickens.

Authors:  M H Al-Zubaidy; F K Mohammad
Journal:  J Vet Sci       Date:  2007-09       Impact factor: 1.603

10.  Effect of several new and currently available oxime cholinesterase reactivators on tabun-intoxicated rats.

Authors:  Jana Zdarova Karasova; Jiri Kassa; Young-Sik Jung; Kamil Musilek; Miroslav Pohanka; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2008-11-14       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.